Abstract: Cannabinoid-loaded formulations are characterized by including 0.5 wt. % to 20 wt. % medium chain triglycerides, one or more hydrophilic surfactants, one or more co-surfactants and 0.1 wt. % or more of at least one cannabinoid. The formulations are in microemulsion form, and are fully dilutable by an aqueous diluent.

Abstract: Provided are cannabinoid-loaded, dilutable microemulsion formulations with low oil content including oleic acid and linoleic acid.

Abstract: A cosmetic composition includes an antimicrobial system that includes an antimicrobial agent comprising 4-hydroxyacetophenone and one or more additional antimicrobial agents comprising piroctone olamine. The antimicrobial system can be used in a cosmetic composition wherein the composition is a makeup removal composition that is one of an O/W emulsion, a W/O emulsion, a micellar water, a makeup removing wipe, or a two-phase (or multi-phase) composition. The antimicrobial system may be free or essentially free of any one or more of parabens, alcohols, formaldehyde, and formaldehyde-derived compounds. In some particular embodiments, the composition is free or essentially free of parabens, formaldehyde, formaldehyde-derived compounds, pentylene glycol, phenoxyethanol, hexylglycerin, ethylhexylglycerin, octylglycerin, benzylglycerin, 3-heptoyl-2,2-propandiol, and 1,2-hexandiol.

Abstract: A thin film transistor array substrate and a touch display panel are provided, including a plurality of touch electrodes. The touch electrodes include a first touch electrode, a second touch electrode, and a third touch electrode arranged along a first direction. A number of the touch traces electrically connected between the second touch electrode and the first common power line is greater than or equal to a number of the touch traces electrically connected between the first touch electrode and the first common power line, and is less than a number of the touch traces electrically connected between the third touch electrode and the first common power line.

Abstract: Cosmetic compositions, kits thereof, and methods of making and using such cosmetic compositions. The cosmetic compositions typically include about 20 to about 95 wt. % of a polyol; about 5 to about 70 wt. % of one or more monoalcohols having from 2 to 6 carbon atoms; about 0.1 to about 10 wt. % of one or more cationic surfactants; about 0.1 to about 20 wt. % of one or more fatty compounds; and about 1 to about 15 wt. % of a combination of a urea compound and citric acid, wherein all weight percentages are based on the total weight of the cosmetic composition. The cosmetic compositions have a weight ratio of polyol to monoalcohol(s) that is from 20:1 to 1:20. Additionally, the cosmetic compositions typically have a mole ratio of citric acid to urea compound of that is about 10:0.5 to about 0.5:10.

Abstract: A liquid crystal coherent transparent display screen and a liquid crystal-laser transparent display system are provided. The liquid crystal coherent transparent display screen includes a first substrate, a second substrate, a first electrode layer, a first partial reflector, a first alignment layer, a second electrode layer, a second partial reflector, a second alignment layer, and a liquid crystal layer. The first partial reflector and the second partial reflector form an optical resonant microcavity, to replace the polarizer, the analyzer and the optical filters in conventional technology, thereby improving the light transmittance of liquid crystal transparent display.

Abstract: A composition for reducing unpleasant odor, the composition includes betaine; musk; and N-Soya-N-ethyl morpholinium ethosulfate.

Abstract: An embedded touch panel display device includes: a display unit having a display surface and a non-display surface opposite to the display surface; a touch-control unit disposed inside the display unit; a conductive frame disposed on one side of the display unit and facing the non-display surface thereof; an insulating ink and a first conductive ink disposed on at least one sidewall of the display unit and extended to the non-display surface, in which the first conductive ink overlaps the insulating ink; and a double-sided adhesive disposed between the display unit and the conductive frame to secure them. The first conductive ink and the conductive frame are electrically connected to each other to form an electrostatic discharge path. The present invention can prevent the peripheral area of the viewed area from a blackening phenomenon induced by excessively high electrostatic voltage.

Abstract: A display device includes an optical film having a via hole; a display panel disposed on a surface of a side of the optical film, and the display panel comprises a transparent area opposite to the via hole; a camera inserted into the via hole and facing the transparent area; and a transparent light source located within the via hole and between the camera and the transparent area.

Abstract: An antiperspirant and/or deodorant composition including from 0.01 weight % to 0.15 weight % flaxseed oil and from 0.5 weight % to 5.0 weight % taurine.

Abstract: A cosmetic composition comprising, in an aqueous cosmetically acceptable medium: a) from 6% to 50% by weight in active material of at least one aqueous polyurethane dispersion; and b) from 2% to 8% by weight of at least one cross-linked starch, the weight being expressed by weight of the total weight of the composition.

Abstract: Provided is an oral soft gel capsule that includes a psychedelic compound. Also provided is a method of treating in a subject a disease or disorder ameliorated by a psychedelic compound, that includes orally administering to a subject an oral soft gel capsule that includes a therapeutically effective amount of the psychedelic compound. Also provided is a method of orally administering to a subject an oral soft gel capsule that includes a therapeutically effective amount of the psychedelic compound. Also provided is a method of orally administering to a subject an oral soft gel capsule that includes a low dose (e.g., microdose or sub-therapeutic dose) of the psychedelic compound.

Abstract: Electronic devices may be provided having internal components mounted to a structural glass support member. The structural glass support member may have a planar front surface that forms a front surface of the device. The structural glass support member may have bent portions that form sidewall surfaces of the device. Portions of the structural glass support member may form a transparent display cover layer. A rigid or flexible display may be mounted to the structural glass support member. Additional internal device components may be mounted to the display. A thin enclosure for enclosing the internal components in the device may be mounted to the structural glass support member. The thin enclosure may be mounted to the structural glass support member using a peripheral member. The thin enclosure may be free from attachments to internal components or may be adhesively bonded to one or more internal components.

Abstract: Disclosed is a display device. The display device of the present disclosure may include: a display panel; a frame which is located in a rear of the display panel and to which the display panel is coupled; a substrate which is located between the display panel and the frame and coupled to the frame; and a plurality of light sources which are mounted on the substrate and spaced apart from each other, wherein the substrate may include: an elongated first plate; and a plurality of second plates which extend from the first plate in a direction intersecting with a length direction of the first plate, and are spaced apart from each other in the length direction of the first plate.

Abstract: Described is a cannabinoid-terpenoid solution (CTS) and method of treating a disease state or condition in animals other than humans via cannabinoid-terpenoid therapy. The CTS includes a unique combination of cannabinoids, terpenoids (terpenes), and a lipophilic carrier to allow safely and effectively treat the animal.

Abstract: According to one embodiment, a display device includes a first substrate, a second substrate and a liquid crystal layer. The first substrate includes a first insulating substrate, a scanning line, a signal line, a switching, and a pixel electrode. The liquid crystal layer includes a polymer in a shape of a streak and a liquid crystal molecule. The scanning line includes a conductive layer located between the first insulating substrate and the liquid crystal layer, and a first reflective layer located between the first insulating substrate and the conductive layer and having a reflectance higher than a reflectance of the conductive layer.

Abstract: The present invention has a pixel which includes a first switch, a second switch, a third switch, a first resistor, a second resistor, a first liquid crystal element, and a second liquid crystal element. A pixel electrode of the first liquid crystal element is electrically connected to a signal line through the first switch. The pixel electrode of the first liquid crystal element is electrically connected to a pixel electrode of the second liquid crystal element through the second switch and the first resistor. The pixel electrode of the second liquid crystal element is electrically connected to a Cs line through the third switch and the second resistor. A common electrode of the first liquid crystal element is electrically connected to a common electrode of the second liquid crystal element.

Abstract: Transdermal therapeutic system for the transdermal administration of a systemically active agent comprising a self-adhesive layer structure, comprising A) a backing layer, and B) a dried biphasic layer, the dried biphasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and b) an inner phase having a composition comprising at least one active agent, wherein the inner phase forms dispersed deposits in the outer phase, and c) 0.1% to 3.5% of an interface mediator with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25° C., and C) optionally an additional skin contact layer.

Abstract: The present invention relates to a composition for stimulating muscle growth, repair and maintenance and the method of using the same. The present invention generally relates to compositions and methods for supporting muscle anabolism. The compositions described herein are pharmaceutical or nutritional compositions suitable for preserving muscle mass, strength, and/or function in a subject in need thereof. The compositions are based on a specially formulated mixture of essential amino acids (EAAs) and protein with additional components. Use of the compositions herein may prevent muscle atrophy associated with periods of rest, such as those following surgery, injury, inactivity and during recovery from disease.

Abstract: Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.